Slaughter and May and Freshfields Bruckhaus Deringer are among four firms to have taken roles on the demerger of Reckitt Benckiser’s pharmaceutical business.
Slaughters corporate partners Rebecca Cousin and Jeff Twentyman are leading for Reckitt and Indivior, the company’s addiction control-focused pharma division, which will be demerged from the FTSE 100 group once shareholder approval is granted in December.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
